Japanese

TAKEUCHI Masayoshi

■Faculty	Department of Advanced Medicine
■Position	Professor

Researcher Profile & Settings

Research

Overview of research:

Involvement of toxic AGEs (TAGE) as new targets in the onset and progression of the lifestyle-related disease and inhibition thereof.

Special Field

Medical, Dental, and Pharmaceutical Science

Education

Hokuriku University Graduate School
Hokuriku University Faculty of Pharmaceutical Science

Degree

Doctor of Pharmacy

Academic & Professional Experience

Apr. 2011Medical Research Institute, Kanazawa Medical University Professor

Research Activities

Published Papers

Potential of an interorgan network mediated by toxic advanced glycation end-products in a rat model, Shinya Inoue, Takanobu Takata, Yusuke Nakazawa, Yuka Nakamura, Xin Guo, Sohsuke Yamada, Yasuhito Ishigaki, Masayoshi Takeuchi, Katsuhito Miyazawa, Nutrients, 13:80, 2020
Exploration of the mystery of the third glycogen metabolite 1,5-anhydro-D-fructose (1,5-AF), Akiko Sakasai-Sakai, Takanobu Takata, Hirokazu Suzuki, Ikuro Maruyama, Kenji Tanaka, Yoshihiro Motomiya, Masayoshi Takeuchi, The Journal of Japan Mibyou Association, 26:67-72, Jan. 2020
Impact of intracellular glyceraldehyde-derived advanced glycation end-products on human hepatocyte cell death, Akiko Sakasai-Sakai, Takanobu Takata, Jun-ichi Takino, Masayoshi Takeuchi, 7:1, Oct. 2017
Toxic AGEs (TAGE) theory: a new concept for preventing the development of diseases related to lifestyle, Takeuchi M, Diabetology & Metabolic Syndrome, 12:105, Nov. 2020
Intracellular toxic advanced glycation end-products promote the production of reactive oxygen species in HepG2 cells, Sakasai-Sakai A, Takata T, Takeuchi M, International Journal of Molecular Sciences, 21:4861, Jul. 2020
The effect of glyceraldedehyde-derived advanced glycation end products on β-tublin-inhibited neurite outgrowth in SH-SY5Y human neuroblastoma cells, (Nasu R), Furukawa A, Suzuki K, Takeuchi M, Koriyama Y, Nutrients, 12:2958, Sep. 2020
Impact of intracellular toxic advanced glycation end-products (TAGE) on murine myoblast cell death, Takata Takanobu, Sakasai-Sakai Akiko, Takeuchi Masayoshi, Diabetology & Metabolic Syndrome, 12:54, Jun. 2020
DOI:10.1186/s13098-020-00561-z
Intracellular toxic advanced glycation end-products in cardiomyocytes may cause cardiovascular disease, Takata Takanobu, Sakasai-Sakai Akiko, Ueda Tadashi, Takeuchi Masayoshi, Scientific Reports, 9:2121, Feb. 2019
DOI:10.1038/s41598-019-39202-5
Evidence for toxic advanced glycation end-products generated in the normal rat liver, Takata Takanobu, Sakasai-Sakai Akiko, Takino Jun-ichi, Takeuchi Masayoshi, Nutrients, 11:1612, Jul. 2019
DOI:10.3390/nu11071612
The relevance of toxic AGEs (TAGE) cytotoxicity to NASH pathogenesis: A mini-review, Sakasai-Sakai Akiko, Takata Takanobu, Takino Jun-Ichi, Takeuchi Masayoshi, Nutrients, 11:462, Feb. 2019
DOI:10.3390/nu11020462
Immunological evidence for in vivo production of novel advanced glycation end-products from 1,5-anhydro-D-fructose, a glycogen metabolite, Sakasai-Sakai Akiko, Takata Takanobu, Suzuki Hirokazu, Maruyama Ikuro, Motomiya Yoshihiro, Takeuchi Masayoshi, Scientific Reports, 9:10194, Jul. 2019
DOI:10.1038/s41598-019-46333-2
Toxic AGEs (TAGE) theory for pathophysiology of the onset / progression of NAFLD and ALD, Akiko Sakasai-Sakai, Jun-ichi Takano, Atsushi Fukumura, Takanobu Takata, Mikihiro Tsutsumi, Masayoshi Takeuchi, The journal of Japan Mibyo System Association, 24:19-25, Mar. 2018
Novel biomarker toxic AGEs (TAGE) in the onset / progression of lifestyle-related (LSRD), Takanobu Takata, Akiko Sakasai-Sakai, Masayoshi Takeuchi, The journal of Japan Mibyo System Association, 24:27-33, Aug. 2018
Effect of Collagen Tripeptide on Atherosclerosis in Healthy Humans, Naohisa Tomosugi, Shoko Yamamoto, Masayoshi Takeuchi, Hideto Yonekura, Yasuhito Ishigaki, Noriaki Numata, Shogo Katsuda, Yasuo Sakai, Journal of Atherosclerosis and Thrombosis, 24:530-538, May 2017
Diurnal glycemic fluctuation is associated with severity of coronary artery disease in prediabetic patients: Possible role of nitrotyrosine and glyceraldehyde-derived advanced glycation end products., M.Watanabe, Y.Kawai, M.Kitayama, H.Akao, A.Motoyama, M.Wakasa , R.Saito, H.Aoki, K.Fujibayashi, T.Tsuchiya, H.Nakanishi, K.Saito, M.Takeuchi, K.Kajinami, Journal of Cardiology, 69:625-631, Apr. 2017
DOI:10.1016/j.jjcc.2016.07.001
Role of Glyceraldehyde-Derived AGEs and Mitochondria in Superoxide Production in Femoral Artery of OLETF Rat and Effects of Pravastatin, (Hori, Eisei);Kikuchi, Chigusa;Nagami, Chie;Kajikuri, Junko;Itoh, Takeo;Takeuchi, Masayoshi;Matsunaga, Tamihide, BIOLOGICAL & PHARMACEUTICAL BULLETIN, 40:1903-1908, Nov. 2017
Ratio of serum levels of AGEs to soluble RAGE is correlated with trimethylamine-N-oxide in non-diabetic subjects, (Tahara, Atsuko);Tahara, Nobuhiro;Yamagishi, Sho-ichi;Honda, Akihiro;Igata, Sachiyo;Nitta, Yoshikazu;Bekki, Munehisa;Nakamura, Tomohisa;Sugiyama, Yoichi;Sun, Jiahui;Takeuchi, Masayoshi;Shimizu, Makiko;Yamazaki, Hiroshi;Fukami, Kei;Fukumoto, Yoshihiro, INTERNATIONAL JOURNAL OF FOOD SCIENCES AND NUTRITION, 68:1013-1020, Apr. 2017
DOI:10.1080/09637486.2017.1318117
High doses of antipsychotic polypharmacy are related to an increase in serum levels of pentosidine in patients with schizophrenia., (Sannohe Takahiro);Ohnuma Tohru;Takeuchi Masayoshi;Tani Eriko;Miki Yasue;Takeda Mayu;Katsuta Narimasa;Takebayashi Yuto;Nakamura Toru;Nishimon Shohei;Kimoto Ayako;Higashiyama Ryoko;Shibata Nobuto;Gohda Tomohito;Suzuki Yusuke;Yamagishi Sho-Ichi;Tomino Yasuhiko;Arai Heii, Progress in Neuro-Psychopharmacology & Biological Psychiatry, 76:42-48, Jun. 2017
DOI:10.1016/j.pnpbp.2017.02.019
Glyceraldehyde-Derived Advanced Glycation End Products Accumulate Faster Than N-epsilon-(Carboxymethyl) Lysine, (Yokota, Mami);Sekita, Marie;Okano, Yuri;Masaki, Hitoshi;Takeuchi, Masayoshi;Tokudome, Yoshihiro, ANNALS OF DERMATOLOGY, 29:508-511, Aug. 2017
DOI:10.5021/ad.2017.29.4.508
Toxic AGE (TAGE) Theory for the Pathophysiology of the Onset/Progression of NAFLD and ALD, Masayoshi Takeuchi, Jun-ichi Takino, Akiko Sakasai-Sakai, Takanobu Takata, Mikihiro Tsutsumi, Nutrients, 9:634, Jun. 2017
DOI:10.3390/nu9060634
Generation of glyceraldehyde-derived advanced glycation end-products in pancreatic cancer cells and the potential of tumor promotion, Takanobu Takata, Tadashi Ueda, Akiko Sakasai-Sakai, Masayoshi Takeuchi, World Journal of Gastroenterology, 23:4910-4919, Jul. 2017
Gene Expression Changes Associated with the Loss of Heterogeneous Nuclear Ribonucleoprotein M Function, (Jun-ichi Takino), Kentaro Nagamine, Mikoto Suzuki, Akiko Sakasai-Sakai, Masayoshi Takeuchi, Takamitsu Hori, American Journal of Molecular Biology, 7:87-98, Apr. 2017
Involvement of toxic AGEs(TAGE) in the onset / progrssion of nonalcoholic fatty liver disease (NAFLD): A novel prevention strategy, Masayoshi Takeuchi,Akiko Sakasai-Sakai,Takanobu Takata, 23:20-30, 2017
Impact of intracellular glyceraldehyde-derived advanced glycation end-products on human hepatocyte cell death, Akiko Sakasai-Sakai,Takanobu Takata,Jun-ichi Takino,Masayoshi Takeuchi, Scientific Reports, 7:14282, Oct. 2017
Effect of Collagen Tripeptide on Atherosclerosis in Healthy Humans., N.Tomosugi, S.Yamamoto, M.Takeuchi, H.Yonekura, Y.Ishigaki, N.Numata, S.Katsuda, Y.Sakai, Journal of atherosclerosis and thrombosis, 24:530-538, May 2017
Serum Levels of Toxic AGEs (TAGE) May Be a Promising Novel Biomarker for the Onset/Progression of Lifestyle-Related Diseases, M.Takeuchi, Diagnostics, 6:1-22, 2016
DOI:10.3390/diagnostics6020023
Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial)., (M.Shimomura), J.Oyama, M.Takeuchi, Y.Shibata, Y.Yamamoto, T.Kawasaki, H.Komoda, K.Kodama, M.Sakuma, S.Toyoda, Y.Inoue, Mine Daigo, M.Natsuaki, A.Komatsu, Y.Hikichi, S.Yamagishi, T.Inoue , K.Node, Heart and vessels, 31:1583-1589, 2016
DOI:10.1007/s00380-015-0773-y
Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma, (J.Takino), K.Nagamine, T.Hori, A.Sakasai-Sakai, M.Takeuchi, World Journal of Hepatology, 7:2459-2469, Aug. 2015
Toxic AGEs (TAGE) theory in the pathogenesis of NAFLD and ALD, M.Takeuchi, A.Sakasai-Sakai, J.Takino, T.Takata, T.Ueda, M.Tsutsumi, International Journal of Diabetes and Clinical Researsh, 2:1-5, Jul. 2015
Usefulness of toxic AGEs (TAGE) as a biomarker for fertility treatment, A.Sakasai-Sakai, M.Jinno, M.Takeuchi, Meeting of the Japan Mibyou System Association, 21:93, Mar. 2015
Involvement of toxic AGEs(TAGE) in the onset/deterioration of lifestyle-related diseases -New preventive strategy-:-Toxic truth about dietary AGEs and sugars-, M.Takeuchi, J.Takino, A.Sakasai-Sakai, T.Takata, T.Ueda , Journal of Kanazawa Medical University, 40:95-103, 2015
The association between glyceraldehyde-derived advanced glycation end-products and colorectal cancer risk, (S.Y.Kong), M.Takeuchi, H.Hyogo, G.McKeown-Eyssen, S.Yamagishi, K.Chayama, P.J.O'Brien, P.Ferrari, K.Overvad, A.Olsen, A.Tjonneland, M.Boutron-Ruault, N.Bastide, F.Carbonnel, T.Kuehn, R.Kaaks, H.Boeing, K.Aleksandrova, A.Trichopoulou, P.Lagiou, E.Vasilopoulou, G.Masala, V.Pala, M.D.Magistris, R.Tumino, A.Naccarati, H.B.Bueno-De-Mesquita, P.H.Peeters, E.Weiderpass, J.R.Quiros, P.Jakszyn, M.Sanchez, M.Dorronsoro, D.Gavrila, E.Ardanaz, M.Rutegard, H.Nystroem, N.Wareham, K.Khaw, K.Bradbury, I.Romieu, H.Freisling, F.Stavropoulou, M.J.Gunter, A.J.Cross, E.Riboli, M.Jenab, W.R.Bruce, Cancer Epidemiology Biomarkers & Prevention, 24:1855-1863, 2015
DOI:10.1158/1055-9965.EPI-15-0422
Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH., M.Takeuchi, A.Sakasai-Sakai, T.Takata, T.Ueda, J.Takino, M.Tsutsumi, H.Hyogo, S.Yamagishi, Medical Hypotheses, 84:490-493, 2015
Ratio of serum levels of AGEs to soluble form of RAGE is a predictor of endothelial function, (M.Kajikawa), A.Nakashima, N.Fujimura, T.Maruhashi, Y.Iwamoto, A.Iwamoto, T.Matsumoto, N.Oda, T.Hidaka, Y.Kihara, K.Chayama, C.Goto, Y.Aibara, K.Noma, M.Takeuchi, T.Matsui, S.Yamagishi, Y.Higashi, Diabetes Care, 38:119-125, 2015
DOI:10.2337/dc14-1435
Oral L-Carnitine Supplementation Increases Trimethylamine-N-oxide but Reduces Markers of Vascular Injury in Hemodialysis Patients, (K.Fukami), S.Yamagishi, K.Sakai, Y.Kaida, M.Yokoro, S.Ueda, Y.Wada, M.Takeuchi, M.Shimizu, H.Yamazaki, S.Okuda, Journal of Cardiovascular Pharmacology, 65:289-295, 2015
DOI:10.1097/FJC.0000000000000197
In vitro identification of nonalcoholic fatty liver disease-related protein hnRNPM, (J.Takino), K.Nagamine, M.Takeuchi, T.Hori, World Journal of Gastroenterology, 21:1784-1793, 2015
DOI:10.3748/wjg.v21.i6.1784
Glyceraldehyde caused Alzheimer's disease-like alterations in diagnostic marker levels in SH-SY5Y human neuroblastoma cells, (Y.Koriyama), A.Furukawa, M.Muramatsu, J.Takino, M.Takeuchi, Scientific Reports, 5:1-7, 2015
DOI:10.1038/srep13313
Elevation of serum levels of advanced glycation end products in patients with non-B or non-C hepatocellular carcinoma, (H.Kan), S.Yamagishi, A.Ojima, K.Fukami, S.Ueda, M.Takeuchi, H.Hyogo, H.Akita, K.Chayama, Journal of Clinical Laboratory Analysis, 29:480-484, 2015
DOI:10.1002/jcla.21797
Clinical and biochemical factors associated with area and metabolic activity in the visceral and subcutaneous adipose tissues by FDG-PET/CT, (N.Tahara), S.Yamagishi, N.Kodama, A.Tahara, A.Honda, Y.Nitta, S.Igata, T.Matsui, M.Takeuchi, H.Kaida, S.Kurata, T.Abe, Y.Fukumoto, Journal of Clinical Endocrinology & Metabolism, 100:E739-E747, 2015
DOI:10.1210/jc.2014-3896
Assessment of total sugar and glucose concentrations in commonly consumed beverages in Japan, M.Takeuchi, J.Takino, H.Shirai, M.Kawakami, S.Furuno, Y.Kobayashi, Nutrition and Food Technology:Open Access, 1:1-9, 2015
Assessment of the concentrations of various advanced glycation end-products in beverages and foods that are commonly consumed in Japan, M.Takeuchi, J.Takino, S.Furuno, H.Shirai, M.Kawakami, M.Muramatsu, Y.Kobayashi, S.Yamagishi, PLoS One, 10:e0118652-e0118652, 2015
DOI:10.1371/journal.pone.0118652
Altered serum glyceraldehyde-derived advanced glycation end product (AGE) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia, (M.Takeda), T.Ohnuma, M.Takeuchi, N.Katsuta, H.Maeshima, Y.Takebayashi, M.Higa, T.Nakamura, S.Nishimon, T.Sannohe, Y.Hotta, R.Hanzawa, R.Higashiyama, N.Shibata, T.Gohda, Y.Suzuki, S.Yamagishi, Y.Tomino, H.Arai, Neuroscience Letters, 593:51-55, 2015
DOI:10.1016/j.neu1et.2015.03.002
Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies., M.Takeuchi, J.Takino, A.Sakasai-Sakai, T.Takata, T.Ueda, M.Tsutsumi, H.Hyogo, S.Yamagishi, World journal of hepatology [electronic resource], 6:880-893, Dec. 2014
Amelioration of experimental autoimmune uveoretinitis by inhibition of glyceraldehyde-derived advanced glycation end-product formation., (Z.Dong), D.Iwata, N.Kitaichi, M.Takeuchi, M.Sato, N.Endo, K.Iwabuchi, R.Ando, J.Fukuhara, S.Kinoshita, A.Lennikov, M.Kitamura, K.Mizuuchi, A.Kanda, K.Noda, K.Namba, S.Yamagishi, S.Ohno, S.Ishida, Journal of leukocyte biology, 96:1077-1085, Dec. 2014
Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients., (K.Yanagisawa), J.Ashihara, S.Obata, N.Wada, M.Takeuchi, Y.Nishino, S.Maeda, Y.Ishibashi, S.Yamagishi, Diabetes/metabolism research and reviews, 30:693-700, Nov. 2014
DOI:10.1002/dmrr.2537
Sulforaphane inhibits advanced glycation end product-induced pericyte damage by reducing expression of receptor for advanced glycation end products., (S.Maeda), T.Matsui, A.Ojima, M.Takeuchi, S.Yamagishi, Nutrition research., 34:807-813, Sep. 2014
DOI:10.1016/j.nutres.2014.08.010
Linagliptin blocks renal damage in type 1 diabetic rats by suppressing advanced glycation end products-receptor axis., (S.Nakashima), T.Matsui, M.Takeuchi, S.Yamagishi, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 46:717-721, Sep. 2014
Effect of statins on the serum soluble form of receptor for advanced glycation end-products and its association with coronary atherosclerosis in patients with angina pectoris., (T.Nozue), S.Yamagishi, M.Takeuchi, T.Hirano, S.Yamamoto, S.Tohyama, K.Fukui, S.Umezawa, Y.Onishi, T.Kunishima, K.Hibi, M.Terashima, I.Michishita, IJC metabolic & endocrine., 4:47-52, Jul. 2014
Advanced glycation end products impair glucose-induced insulin secretion from rat pancreatic β-cells., (H.Hachiya), Y.Miura, K.Inoue, K.H.Park, M.Takeuchi, K.Kubota, Journal of hepato-biliary-pancreatic sciences., 21:134-141, Feb. 2014
Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report., (I.Nakamura), J.Oyama, H.Komoda, A.Shiraki, Y.Sakamoto, I.Taguchi, A.Hiwatashi, A.Komatsu, M.Takeuchi, S.Yamagishi, T.Inoue, K.Node, Cardiovascular diabetology [electronic resource], 13:15;1-8, Jan. 2014
DOI:10.1186/1475-2840-13-15
DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice, Ojima, Ayako;Matsui, Takanori;Maeda, Sayaka;Takeuchi, Masayoshi;Inoue, Hiroyoshi;Higashimoto, Yuichiro;Yamagishi, Sho-ichi, LABORATORY INVESTIGATION, 94:422-429, 2014
DOI:10.1038/labinvest.2014.5
Amelioration of experimental autoimmune uveoretinitis by inhibition of glyceraldehyde-derived advanced glycation end-product formation, Dong, Zhenyu;Iwata, Daiju;Kitaichi, Nobuyoshi;Takeuchi, Masayoshi;Sato, Masashi;Endo, Noriko;Iwabuchi, Kazuya;Ando, Ryo;Fukuhara, Junichi;Kinoshita, Satoshi;Lennikov, Anton;Kitamura, Mizuki;Mizuuchi, Kazuomi;Kanda, Atsuhiro;Noda, Kousuke;Namba, Kenichi;Yamagishi, Sho-Ichi;Ohno, Shigeaki;Ishida, Susumu, JOURNAL OF LEUKOCYTE BIOLOGY, 96:1077-1085, 2014
DOI:10.1189/jlb.3A0513-288RRR
Advanced glycation end products impair glucose-induced insulin secretion from rat pancreatic -cells, Hachiya, Hiroyuki;Miura, Yoshikazu;Inoue, Ken-ichi;Park, Kyung Hwa;Takeuchi, Masayoshi;Kubota, Keiichi, JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 21:134-141, 2014
DOI:10.1002/jhbp.12
Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product(AGE) - receptor for AGE(RAGE) axis, and albuminuria in Japanese type 2 diabetes., (K.Sakata), M.Hayakawa, Y.Yano, N.Tamaki, N.Yokota, T.Eto, R.Watanabe, N.Hirayama, T.Matsuo, K.Kuroki, S.Sagara, O.Mishima, M.Koga, N.Nagata, Y.Nishino, K.Kitamura, K.Kario, M.Takeuchi, S.Yamagishi, Diabetes/metabolism research and reviews, 29:624-630, Nov. 2013
Blockade by phosphorothioate aptamers of advanced glycation end products-induced damage in cultured pericytes and endothelial cells., (Y.Higashimoto), T.Matsui, Y.Nishino, J.Taira, H.Inoue, M.Takeuchi, S.Yamagishi, Microvascular research, 90:64-70, Nov. 2013
Presence of glyceraldehyde-derived advanced glycation end-products in the liver of insulin-resistant mice, (Y.Ebata), J.Takino, H.Tsuchiya, T.Sakabe, Y.Ikeda, S.Hama, K.Kogure, M.Takeuchi, G.Shiota, International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition., 83:137-141, Sep. 2013
Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction., (R.Ando), S.Ueda, S.Yamagishi, H.Miyazaki, Y.Kaida, K.Kaifu, M.Yokoro, Y.Nakayama, N.Obara, K.Fukami, M.Takeuchi, S.Okuda, Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease., 10:436-441, Sep. 2013
DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy, Higashimoto, Yuichiro;Kaida, Yusuke;Matsui, Takanori;Fukami, Kei;Okuda, Seiya;Yamagishi, Sho-ichi;Takeuchi, Masayoshi;Inoue, Hiroyoshi, JOURNAL OF PHARMACOLOGICAL SCIENCES, 124:225P-225P, Sep. 2013
DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy, (Y.Kaida), K.Fukami, T.Matsui, Y.Higashimoto, Y.Nishino, N.Obara, Y.Nakayama, R.Ando, M.Toyonaga, S.Ueda, M.Takeuchi, H.Inoue, S.Okuda, S.Yamagishi, Diabetes., 62:3241-3250, Sep. 2013
Asymmetrical dimethylarginine level is independently associated with circulating levels of RAGE and PEDF, (N.Tahara), S.Yamagishi, A.Tahara, M.Takeuchi, T.Imaizumi, International journal of cardiology, 167:3072-3074, Sep. 2013
Telmisartan inhibits AGE-induced podocyte damage and detachment., (K.Fukami), S.Yamagishi, K.Kaifu, T.Matsui, Y.Kaida, S.Ueda, M.Takaeuchi, K.Asanuma, S.Okuda, Microvascular research, 88:79-83, Jul. 2013
Sodium-glucose cotransporter 2-mediated oxidative stress augments advanced glycation end products-induced tubular cell apoptosis., (S.Maeda), T.Matsui, M.Takeuchi, S.Yamagishi, Diabetes/metabolism research and reviews, 29:406-412, Jul. 2013
Acetaldehyde-derived advanced glycation end-products promote alcoholic liver disease., N.Hayashi, J.George, M.Takeuchi, A.Fukumura, N.Toshikuni, T.Arisawa, M.Tsutsumi, PloS one, 8:e70034;1-14, Jul. 2013
Serum levels of advanced glycation end-products (AGEs) in dialysis patients -Effects of low-dose sevelamer hydrochloride-, (H.Muramoto), H.Mutoh, M.Takeuchi, 46:467-473, May 2013
Nighttime blood pressure, nighttime glucose values, and target-organ damages in treated type 2 diabetes patients., (Y.Yano), M.Hayakawa, K.Kuroki, H.Ueno, S.Yamagishi, M.Takeuchi, T.Eto, N.Nagata, M.Nakazato, K.Shimada, K.Kario, Atherosclerosis., 227:135-139, Mar. 2013
Relationship between advanced glycation end products and plaque progression in patients with acute coronary syndrome: The JAPAN-ACS sub-study., (Y.Fukushima), H.Daida, T.Morimoto, T.Kasai, K.Miyauchi, S.Yamagishi, M.Takeuchi, T.Hiro, T.Kimura, Y.Nakagawa, M.Yamagishi, Y.Ozaki, M.Matsuzaki, Cardiovascular diabetology [electronic resource], 0.503472222, Jan. 2013
PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation., (Y.Ishibashi), T.Matsui, K.Ohta, R.Tanoue, M.Takeuchi, K.Asanuma, K.Fukami, S.Okuda, K.Nakamura, S.Yamagishi, Microvascular research, 85:54-58, Jan. 2013
Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression., (A.Ojima), Y.Ishibashi, T.Matsui, S.Maeda, Y.Nishino, M.Takeuchi, K.Fukami, S.Yamagishi, The American journal of pathology., 182:132-141, Jan. 2013
Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans., (N.Tahara), S.Yamagishi, M.Takeuchi, A.Tahara, K.Kaifu, S.Ueda, S.Okuda, T.Imaizumi, Clinical biochemistry, 46:300-303, Dec. 2012
Positive association between serum level of glyceraldehyde-derived advanced glycation end products (AGEs) and vascular inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography (FDG-PET)., (N.Tahara), S.Yamagishi, M.Takeuchi, A.Honda, A.Tahara, Y.Nitta, N.Kodama, M.Mizoguchi, H.Kaida, M.Ishibashi, N.Hayabuchi, T.Matshui, T.Imaizumi, Diabetes Care., 35:2618-2625, Dec. 2012
Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase., (Y.Ishibashi), T.Matsui, M.Takeuchi, S.Yamagishi, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 45:387-390, Dec. 2012
Serum levels of pigment epithelium-derived factor, a novel marker of insulin resistance, are independently associated with fasting apolipoprotein B48 levels in humans, (N.Tahara), S.Yamagishi, A.Tahara, M.Takeuchi, T.Imaizumi, Clinical biochemistry, 45:1404-1408, Nov. 2012
Metoformin inhibits advanced glycation end products (AGEs)-induced renal tubular cell injury by suppressing reactive oxygen species generation via reducing receptor for AGEs (RAGE) expression., (Y.Ishibashi), T.Matsui, M.Takeuchi, S.Yamagishi, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 44:891-895, Nov. 2012
Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level., (Y.Ishibashi), S.Yamagishi, T.Matsui, K.Ohta, R.Tanoue, M.Takeuchi, S.Ueda, K.Nakamura, S.Okuda, Metabolism: clinical and experimental, 61:1067-1072, Aug. 2012
Adiponectin is inversely associated with ratio of serum levels of AGEs to sRAGE and vascular inflammation., (N.Tahara), S.Yamagishi, A.Tahara, M.Ishibashi, N.Hayabuchi, M.Takeuchi, T.Imaizumi, International journal of cardiology, 158:461-462, Jul. 2012
Glucose-dependent insulinotropic polypeptide (GIP) inhibits signaling pathways of advanced glycation end products (AGEs) in endothelial cells via its anti-oxidative properties., (A.Ojima), T.Matsui, S.Maeda, M.Takeuchi, S.Yamagishi, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 44:501-505, Jun. 2012
Glycer-AGEs-RAGE signaling enhances the angiogenic potential of HCC by upregulating VEGF expression., (J.Takino), S.Yamagishi, M.Takeuchi, World journal of gastroenterology : WJG., 18:1781-1788, Apr. 2012
Beneficial effects of metformin and irbesartan on advanced glycation end products (AGEs)-RAGE-induced proximal tubular cell injury., (Y.Ishibashi), T.Matsui, M.Takeuchi, S.Yamagishi, Pharmacological research : the official journal of the Italian Pharmacological Society., 65:297-302, Mar. 2012
AGEs and Liver Disease, Anti-Aging Medicine, 8:55-61, Feb. 2012
Pigment epithelium-derived factor (PEDF) blocks advanced glycation end products (AGEs)- RAGE-induced suppression of adiponectin mRNA level in adipocytes by inhibiting NADPH oxidase- mediated oxidative stress generation, (S.Maeda), T.Matsui, M.Takeuchi, S.Yamagishi, International journal of cardiology, 152:408-410, Nov. 2011
Sitagliptin augments suppressive effects of GLP-1 on advanced glycation end product (AGE)-receptor axis in endothelial cells, (Y.Ishibashi), T.Matsui, M.Takeuchi, S.Yamagishi, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 43:731-734, Sep. 2011
Glucagon-like peptide-1 suppresses advanced glycation end product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing AGE receptor level, (Y.Ishibashi), Y.Nishino, T.Matsui, M.Takeuchi, S.Yamagishi, Metabolism: clinical and experimental, 60:1271-1277, Sep. 2011
Rosuvastatin blocks advanced glycation end products-elicited reduction of macrophage cholesterol efflux by suppressing NADPH oxidase activity via inhibition of geranylgeranylation of Rac-1, (Y.Ishibashi), T.Matsui, M.Takeuchi, S.Yamagishi, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 43: 619-624, Aug. 2011
Activation of receptor for advanced glycation end products induces osteogenic differentiation of vascular smooth muscle cells., (T.Suga), T.Iso, T.Shimizu, T.Tanaka, S.Yamagishi, M.Takeuchi, T.Imaizumi, M.Kurabayashi, Journal of atherosclerosis and thrombosis., 18:670-683, Aug. 2011
Vardenafil, an inhibitor of phosphodiesterase-5, blocks advanced glycation end product (AGE)-induced up-regulation of monocyte chemoattractant protein-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression via elevation of cGMP., (Y.shibashi), T.Matsui, M.Takeuchi, S.Yamagishi, Clinical and experimental medicine, 11:131-135, Jun. 2011
Calcium channel blocker inhibition of AGE and RAGE axis limits renal injury in nondiabetic patients with stage I or II chronic kidney disease, (T.Nakamura), E.Sato, N.Fujuwara, Y.Kawagoe, H.Koide, Y.Ueda, M.Takeuchi, S.Yamagishi, Clinical cardiology., 34:372-377, Jun. 2011
Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis, (T.Matsui), Y.Nishino, M.Takeuchi, S.Yamagishi, Pharmacological research : the official journal of the Italian Pharmacological Society., 63:383-388, Mar. 2011
Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis., (Maeda S), Matsui T, Takeuchi M, Yoshida Y, Yamakawa R, Fukami K, Yamagishi S, Pharmacological research : the official journal of the Italian Pharmacological Society., 63: 241-248, Mar. 2011
Irbesartan inhibits advanced glycation end product (AGE)-induced up-regulation of vascular cell adhesion molecule-1 (VCAM-1) mRNA levels in glomerular endothelial cells, (T.Matsui), Y.Nishino, S.Maeda, M.Takeuchi, S.Yamagishi, Microvascular research, 81:269-273, Mar. 2011
Combination therapy with nateglinide and telmisartan ameliorates insulin resistance in Zucker fatty rats by suppressing advanced glycation end product receptor axis., (Miura K), Kitahara Y, Kajioka T, Takeuchi M, Yamagishi S, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 43: 226-228, Mar. 2011
Advanced glycation end-products accumulation compromises embryonic development and achievement of pregnancy by assisted reproductive technology., (Jinno M), Takeuchi M, Watanabe A, Teruya K, Hirohama J, Eguchi N, Miyazaki A, Human reproduction (Oxford, England), 26: 604-610, Mar. 2011
Co-treatement with azelinidipine and olmesartan inhibits advanced glycation end products (AGEs)-elicited down-regulation of adiponectin mRNA levels in cultured adipocytes partly via its anti-oxidative property., (Maeda S), Matsui T, Takeuchi M, Yamagishi S, International journal of cardiology, 146: 264-266, Feb. 2011
Involvement of aldosterone-mineralcorticoid receptor system in advanced glycation end product (AGE)- elicited plasminogen activator inhibitor-1 (PAI-1) expression in diabetes., (Matsui T), Takeuchi M, Yamagishi S, International journal of cardiology, 145: 566-567, Dec. 2010
MK615 decreases RAGE expression and inhibits TAGE-induced proliferation in hepatocellular carcinoma cells., (Sakuraoka Y), Sawada T, Okada T, Shiraki T, Miura Y, Hiraishi K, Osawa T, Adaci M, Takino J, Takeuchi M, Kubota K, World journal of gastroenterology : WJG., 16: 5334-5341, Nov. 2010
Involvement of the toxic AGEs (TAGE)-RAGE system in the pathogenesis of diabetic vascular complications: A novel therapeutic strategy., Takeuchi M, Takino J, Yamagishi S, Current drug targets, 11: 1468-1482, Nov. 2010
Pigment epithelium-derived factor (PEDF) inhibits diabetes- or advanced glycation end product (AGE)- induced platelet CD40 ligand overexpression in rats., (Yamagishi S), Matsui T, Ueda S, Takeuchi M, International journal of cardiology, 144: 283-285, Oct. 2010
Pyridoxamine, an inhibitor of advanced glycation end product (AGE) formation ameliorates insulin, (Unoki-Kubota H), Yamagishi S, Takeuchi M, Bujo H, Saito Y, Protein and peptide letters, 17: 1177-1181, Sep. 2010
Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation., (Ide Y), Matsui T, Ishibashi Y, Takeuchi M, Yamagishi S, Microvascular research, 80: 227-232, Sep. 2010
Atorvastain reduces proteinuria in non-diabetic chronic kidney disease patients partly via lowering serum levels of advanced glycation end products (AGEs)., (Nakamura T), Sato E, Fujiwara N, Nawagoe Y, Takeuchi M, Maeda S, Yamagishi S, Oxidative medicine and cellular longevity, 3: 304-307, Sep. 2010
Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-, (Matsui T), Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S, Biochemical and biophysical research communications, 398: 326-330, Jul. 2010
Insulin resistence is an independent correlate of high serum levels of advanced glycation end products (AGEs) and low testosterone in non-diabetic men., (Tahara N), Imaizumi T, Takeuchi M, Yamagishi S, Oxidative medicine and cellular longevity, 3: 262-265, Jul. 2010
Immunological detection of fructose-derived advanced glycation end-products., Takeuchi M, Iwaki M, Takino J, Shirai H, Kawakami M, Bucala R, Yamagishi S, Laboratory investigation; a journal of technical methods and pathology., 90: 1117-1127, Jul. 2010
Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH., (Kimura Y), Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K, Journal of gastroenterology., 45: 750-757, Jul. 2010
Involvement of TAGE-RAGE system in the pathogenesis of diabetic retinopathy., Takeuchi M, Takino J, Yamagishi S, Journal of ophthalmology, 2010: 170393, Jun. 2010
Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products., (Takino J), Yamagishi S, Takeuchi M, Journal of oncology., 2010: 739852, Jun. 2010
An α-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes., (Tsunosue M), Mashiko N, Ohta Y, Matsuo Y, Ueda K, Ninomiya M, Tanaka S, Hoshiko M, Yoshiyama Y, Takeuchi M, Ueda S, Yamagishi S, Clinical and experimental medicine, 10: 139-141, Jun. 2010
Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced, (Matsui T), Takeuchi M, Yamagishi S, Biochemical and biophysical research communications, 396: 566-570, May 2010
Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population., (Yamagishi S), Matsui T, Adachi H, Takeuchi M, Pharmacological research : the official journal of the Italian Pharmacological Society., 61: 103-107, Feb. 2010
The formation of intracellular glyceraldehyde-derived advanced glycation end-products and cytotoxicity., (Takino J), Kobayashi Y, Takeuchi M, Journal of gastroenterology., 45: 646-655, Jan. 2010
Neuropathy induced by exogenously administered advanced glycation end-products in rats., (Nishizawa Y), Wada R, Baba M, Takeuchi M, Hanyu-Ishibashi C, Yagihashi S, Journal of diabetes investigation, 1: 40-49, Jan. 2010
Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression., (Matsui T), Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S, Pharmacological research : the official journal of the Italian Pharmacological Society., 61: 34-39, Jan. 2010
Glucagon-like peptide-1 (GLP-1) inihibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression., (Ishibashi Y), Matsui T, Takeuchi M, Yamagishi S, Biochemical and biophysical research communications, 391: 1405-1408, Jan. 2010
Circulating levels of advanced glycation end products (AGE) and interleukin-6 (IL-6) are independent determinants of serum asymmetric dimethylarginine (ADMA) levels in patients with septic shock, (Nakamura T), Sato E, Fujiwara N, Kawagoe W, Suzuki T, Ueda Y, Yamada S, Shoji H, Takeuchi M, Ueda S, Matsui T, Adachi H, Okuda S, Yamagishi S, Pharmacological research : the official journal of the Italian Pharmacological Society., 60: 515-518, Dec. 2009
Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients, (Nakamura T), Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Yamada Y, Takeuchi M, Fukami K, Ueda S, Adachi H, Matsui T, Okuda S, Yamagishi S, Metabolism: clinical and experimental, 58: 1624-1628, Nov. 2009
Low-density lipoprotein levels are one of the independent determinants of circulating levels of advanced glycation end products in nondiabetic subjects, (Yamagishi S), Adachi H, Matsui T, Nakamura K, Takeuchi M, Enomoto M, Fukami A, Otsuka M, Kumagae S, Nanjo Y, ueda S, Imaizumi T, Clinical cardiology., 32: E12-E15, Sep. 2009
Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer’s disease., Takeuchi M, Yamagishi S, Journal of Alzheimer's disease : JAD, 16: 845-858, Aug. 2009
Up-regulation in receptor for advanced glycation end-products in inflammatory circumstances in bovine coccygeal intervertebral disc specimens in vitro, (Yoshida T), Park JS, Yokosuka K, Jinbo K, Yamada K, Sato K, Takeuchi M, Yamagishi S, Nagata K, Spine, 34: 1544-1548, Jul. 2009
Nifedipine, a calcium channel blocker, inhibits advanced glycation end products (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gammma activation, (Matsui T), Yamagishi S, Takeuchi M, Ueda S, Fukami K, Okuda S, Biochemical and biophysical research communications, 385: 269-272, Jul. 2009
Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs), (Yamagishi S), Matsui T, Takenaka K, Nakamura K, Takeuchi M, Inoue H, Diabetes/metabolism research and reviews, 25: 266-271, Mar. 2009
Independent determinants of soluble form of receptor for advanced glycation end products in elderly hypertensive patients, (Nakamura K), Adachi H, Matsui T, Kurita Y, Takeuchi M, Yamagishi S, Metabolism: clinical and experimental, 58: 421-425, Mar. 2009
Effects of high-AGE beverage on RAGE and VEGF expressions in the liver and kidneys, (Sato T), Wu X, Shimogaito N, Takino J, Yamagishi S, Takeuchi M, European journal of nutrition, 48: 6-11, Feb. 2009
Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-defient mice, (You K), Hirayama A, Ishizaki K, Yamada A, Takeuchi M, Yamagishi S, Morito N, Nakano T, Ojima M, Shimokata H, Itoh K, Takahashi S, Yamamoto M, Genes to cells : devoted to molecular & cellular mechanisms, 13: 1159-1170, Nov. 2008
Possible involvement of advanced glycation end products (AGEs) in the pathogenesis of Alzheimer’s disease, Takeuchi M, Yamagishi S, Current pharmaceutical design, 14: 973-978, Oct. 2008
Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation, (Yoshida T), Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, koga H, Ueno T, Sata M, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 40: 620-625, Sep. 2008
Glyceraldehyde-derived advanced glycation end products (AGEs): A novel biomarker of postprandial hyperglycemia in diabetic rats, (Kitahara Y), Takeuchi M, Miura K, Mine T, Matsui T, Yamagishi S, Clinical and experimental medicine, 8: 175-177, Sep. 2008
Telmisartan inhibits advanced glycation end products (AGEs)-elicited endothelial cell injury by suppressing AGE receptor (RAGE) expression via peroxisome proliferators-activated receptor-gamma activation, (Yamagishi S), Matsui T, Nakamura K, Takeuchi M, Inoue H, Protein and peptide letters, 15: 850-853, Aug. 2008
Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are positively associated with circulating AGEs and soluble form of VCAM-1 in patients with type 2 diabetes, (Nakamura K), Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T, Microvascular research, 76: 52-56, May 2008
Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells, (Iwamoto K), Kanno K, Hyogo H, Yamagishi S, Takeuchi M, Tazuma S, Chayama K, Journal of gastroenterology., 43: 298-304, Apr. 2008
Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end-product (AGE)-elicited hepatic insulin resistance via peroxisome proliferator-activated receptor-gamma activation, (Yoshida T), Yamagishi S, Matsui T, Nakamura K, Ueno T, Takeuchi M, Sata M, The Journal of international medical research., 36: 237-243, Mar. 2008
Circulating advanced glycation end products (AGEs) and soluble form of receptor for AGEs (sRAGE) are independent determinants of serum monocyte chemoattractant protein-1 (MCP-1) levels in patients with type 2 diabetes., (Nakamura K), Yamagishi S, Adachi H, Matsui T, Kurita-Nakamura Y, Takeuchi M, Inoue H, Imaizumi T, Diabetes/metabolism research and reviews, 24: 109-114, Feb. 2008
Telmisartan blocks advanced glycation end product (AGE)-induced plasminogen activator inhibitor-1 (PAI-1) gene expression in endothelial cells via activation of peroxisome proliferator-activated receptor-γ (PPAR-γ), (Matsui T), Nakamura K, Takeuchi M, Yamagishi S, Letters in drug design & discovery, 5: 477-480, Jan. 2008
Olmesartan blocks inflammatory reactions in endothelial cells evoked by advanced glycation end products by suppressing generation of reactive oxygen species, (Yamagishi S), Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Okuda S, Imaizumi T, Ophthalmic research., 40: 10-15, Jan. 2008
Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression, (Yamagishi S), Matsui T, Nakamura K, Inoue H, Takeuchi M, Ueda S, Fukami K, Okuda S, Imaizumi T, Microvascular research, 75: 130-134, Jan. 2008
Serum levels of soluble form of receptor for advanced glycation end products (sRAGE) are correlated with AGEs in both diabetic and non-diabetic subjects, (Nakamura K), Yamagishi S, Matsui T, Adachi H, Takeuchi M, Imaizumi T, Clinical and experimental medicine, 7: 188-190, Dec. 2007
Serum level of advanced glycation end-products (AGEs) is an independent determinant of plasminogen activator inhibitor-1 (PAI-1) in nondiabetic general population, (Yamagishi S), Adachi H, Takeuchi M, Enomoto M, Fukami K, Matsui T, Nakamura K, Imaizumi T, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 39: 845-848, Nov. 2007
Pigment epithelium-derived factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxidase synthase (eNOS) reduction through its anti-oxidative properties, (Yamagishi S), Ueda S, Matsui T, Nakamura K, Imaizumi T, Takeuchi M, Okuda S, Protein and peptide letters, 14: 832-835, Aug. 2007
Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advanced glycation end product (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through down-regulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation, (Matsui T), Yamagishi S, Ueda S, Nakamura K, Imaizumi T, Takeuchi M, Inoue H, The Journal of international medical research., 35: 482-489, Jul. 2007
In vitro selection of DNA aptamers that block toxic effects of AGE on cultured retinal pericytes, (Higashimoto Y), Yamagishi S, Nakamura K, Matsui T, Takeuchi M, Noguchi M, Inoue H, Microvascular research, 74: 65-69, Jul. 2007
Elevated levels of serum advanced glycation end-products in patients with nonalcoholic steatohepatitis, (Hyogo H), Yamagishi S, Iwamoto K, Arihiro K, Takeuchi M, Sato T, Ochi H, Nakano M, Nabeshima Y, Inoue M, Ishitobi T, Chayama K, Tazuma S, Journal of gastroenterology and hepatology., 22: 1112-1119, Jul. 2007
Short-chain aldehyde-derived ligands for RAGE and their actions on endothelial cells, (Yamamoto Y), Yonekura H, Watanabe T, Sakurai S, Li H, Harashima A, Myint KM, Osawa M, Takeuchi A, Takeuchi M, Yamamoto H, Diabetes research and clinical practice., 77 Suppl 1: S30-S40, Jun. 2007
Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer’s disease, Takeuchi M, Sato T, Takino J, Kobayashi Y, Furuno S, Kikuchi S, Yamagishi S, Medical hypotheses, 69: 1358-1366, Jun. 2007
Immunohistochemical demonstration of advanced glycation end products and the effects of advanced glycation end products in ossified ligament tissues in vitro., (Yokosuka K), Park JS, Jimbo K, Yoshida T, Yamada K, Sato K, Takeuchi M, Yamagishi S, Nagata K, Spine, 32: E337-E339, May 2007
Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes, (Unoki H), Bujo H, Yamagishi S, Takeuchi M, Imaizumi T, Saito Y, Diabetes research and clinical practice., 76: 236-244, May 2007
Positive correlation between vitreous levels of advanced glycation end products and vascular endothelial growth factor in patients with diabetic retinopathy sufficiently treated with photocoagulation, (Yokoi M), Yamagishi S, Takeuchi M, Matsui T, Yoshida Y, Ohgami K, Amano-Okamoto T, Ohno S, The British journal of ophthalmology., 91: 397-398, Mar. 2007
Pigment epithelium-derived factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro., (Yamagishi S), Nakamura K, Matsui T, Yoshida T, Takeuchi M, Imaizumi T, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 39: 233-235, Mar. 2007
Oral administration of AST-120 (Kremezine) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders, (Yamagishi S), Nakamura K, Matsui T, Inoue H, Takeuchi M, Medical hypotheses, 69: 666-668, Mar. 2007
Pigment epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats, (Yamagishi S), Matsui T, Nakamura K, Yoshida T, Takeuchi M, Inoue H, Yoshida Y, Imaizumi T, Ophthalmic research., 39: 92-97, Feb. 2007
Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-induced expression of monocyte chemoattractant protein-1 in human cultured mesangial cells, (Matsui T), Yamagishi S, Nakamura K, Inoue H, Takeuchi M, The Journal of international medical research., 35: 107-112, Feb. 2007
Atorvastatin inhibits advanced glycation end products (AGE)-induced C-reactive expression in hepatoma cells by suppressing reactive oxygen species generation, (Yoshida T), Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Makino T, Shimuzu T, Sata M, Vascular disease prevention, 4: 213-216, Feb. 2007
Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in patients with type 2 diabetes, (Jinnouchi Y), Yamagishi S, Takeuchi M, Ishida S, Jinnouchi Y, Jinnouchi J, Imaizumi T, Clinical and experimental medicine, 6: 191-193, Dec. 2006
Advanced glycation end-products downregulate intervertebral disc cell production of proteoglycans in vitro, (Yokosuka K), Park JS, Jimbo K, Yamada K, Sato K, Tsuru M, Takeuchi M, Yamagishi S, Nagata K, Journal of neurosurgery. Spine, 5: 324-329, Oct. 2006
Susceptibility of brain microvascular endothelial cells to advanced glycation end products-induced tissue factor upregulation is associated with intracellular reactive oxygen species, (Niiya Y), Abumiya T, Shichinohe H, Kuroda S, Kikuchi S, Ieko M, Yamagishi S, Takeuchi M, Sato T, Iwasaki Y, Brain research., 1108: 179-187, Sep. 2006
RAGE control of diabetic nephropathy in a mouse model: effects of RAGE gene disruption and administration of low molecular weight heparin, (Myint KM), Yamamoto Y, Doi T, Kato I, Harashima A, Yonekura H, Watanabe T, Shinohara H, Takeuchi M, Tsuneyama K, Hashimoto N, Asano M, Takasawa S, Okamoto H, Yamamoto H, Diabetes., 55: 2510-2522, Sep. 2006
Positive association between serum levels of advanced glycation end products and the soluble form of receptor for advanced glycation end products in nondiabetic subjects, (Yamagishi S), Adachi H, Nakamura K, Matsui T, Jinnouchi Y, Takenaka K, Takeuchi M, Enomoto M, Furuki K, Hino A, Shigeto Y, Imaizumi T, Metabolism: clinical and experimental, 55: 1227-1231, Sep. 2006
Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation., (Yoshida T), Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Koga H, Ueno T, Sata M, Diabetologia, 49: 3094-3099, Sep. 2006
Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation., (Yoshida T), Yamagishi S, Nakamura K, Matsui T, Imaizumi T, Takeuchi M, Ueda T, Sata M, FEBS letters, 580: 2788-2796, Sep. 2006
Receptor for advanced glycation end products is involved in impaired angiogenic response in diabetes, (Shoji T), Koyama H, Morikawa T, Tanaka S, Kizu A, Motoyama K, Mori K, Fukumoto S, Shioi A, Shimogaito N, Takeuchi M, Yamamoto Y, Yonekura H, Yamamoto H, Nishizawa Y, Diabetes., 55: 2245-2255, Aug. 2006
Oral adsorbent AST-120 decreases serum levels of AGEs in patients with chronic renal failure, (Ueda S), Yamagishi S, Takeuchi M, Kohno K, Shibata R, Matsumoto Y, Kaneyuki U, Fujimura T, Hayashida A, Okuda S, Molecular medicine (Cambridge, Mass.), 12: 180-184, Aug. 2006
Toxic advanced glycation end product (TAGE) theory in Alzheimer’s disease, (Sato T), Shimogaito N, Wu X, Kikuchi S, Yamagishi S, Takeuchi M, American journal of Alzheimer's disease and other dementias, 21: 197-208, Jul. 2006
Positive association of serum levels of advanced glycation end products with thrombogenic markers in humans, (Enomoto M), Adachi H, Yamagishi S, Takeuchi M, Furuki K, Hino A, Hiratsuka A, Takajo Y, Imaizumi T, Metabolism: clinical and experimental, 55: 912-917, Jul. 2006
Pigment epithelium-derived factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis, (Yamagishi S), Matsui T, Nakamura K, Takeuchi M, Imaizumi T, Microvascular research, 72: 86-90, Jul. 2006
TAGE (toxic AGEs) theory in diabetic complications, (Sato T), Iwaki M, Shimogaito N, Wu X, Yamagishi S, Takeuchi M, Current molecular medicine, 6: 351-358, May 2006
Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy., (Yamagishi S), Nakamura K, Matsui T, Sato T, Takeuchi M, Medical hypotheses, 66:1019-1021, May 2006
Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression, (Yamagishi S), Nakamura K, Matsui T, Inagaki Y, Takenaka K, Jinnouchi Y, Yoshida Y, Matsuura T, Narama I, Motomiya Y, Takeuchi M, Inoue H, Yoshimura A, Bucala R, Imaizumi T, The Journal of biological chemistry., 281: 20213-20220, May 2006
Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell proliferation by suppressing autocrine production of interleukin-2, (Yamagishi S), Kikuchi S, Nakamura K, Matsui T, Takeuchi M, Inoue H, Medicinal chemistry (Sh？riqah (United Arab Emirates)), 2: 265-269, May 2006
Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver., (Yamagishi S), Nakamura K, Matsui K, Sato T, Takeuchi M, Medical hypotheses, 66:844-846, Apr. 2006
Protective role of pravastatin in the pathogenesis of the metabolic syndrome., (Yamagishi S), Matsui T, Sato T, Takeuchi M, Medical hypotheses, 66:609-611, Mar. 2006
Minodronate, a nitrogen-containing bisphosphonate, is a promising remedy for treating patients with diabetic retinopathy., (Yamagishi S), Nakamura K, Matsui T, Takeuchi M, Medical hypotheses, 66:273-275, Feb. 2006
Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhension molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation, (Yamagishi S), Matsui T, Nakamura T, Takeuchi M, International journal of tissue reactions, 27: 189-195, Dec. 2005
Cytotoxicity of acetaldehyde-derived advanced glycation end-products (AA-AGE) in alcoholic-induced neuronal degeneration, Takeuchi M, Saito T, Alcoholism, clinical and experimental research., 29 (12 Suppl): 220S-224S, Dec. 2005
Decerase in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease, (Kitamura M), Kitaichi N, Takeuchi M, Kitamei H, Namba K, Yamagishi S, Iwabuchi K, Onoe K, Ohno S, The British journal of ophthalmology., 89: 1407-1409, Nov. 2005
Blockade by nifedipine of advanced glycation end product-induced CD40-CD40 ligand interaction in endothelial cells, (Yamagishi S), kikuchi S, Takenaka K, Takeuchi M, Drugs under experimental and clinical research, 31: 221-226, Nov. 2005
Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats, (Yamagishi S), Takeuchi M, Inoue H, International journal of tissue reactions, 27: 137-143, Sep. 2005
Angiotensin II augments advanced glycation end product-induced pericyte apoptosis through RAGE overexpression, (Yamagishi S), Takeuchi M, Matsui T, Nakamura K, Imaizumi T, Inoue H, FEBS letters, 579: 4265-4270, Aug. 2005
Olmesartan medoxomil, a newly developed angiotensin II type 1 receptor antagonist, protects against renal damage in advanced glycation end product (AGE)-injected rats, (Yamagishi S), Takeuchi M, Inoue H, Drugs under experimental and clinical research, 31: 45-51, Jun. 2005
Met72Thr polymorphism of pigment epithelium-derived factor (PEDF) gene and susceptibility to age-related macular degeneration., (Yamagishi S), Nakamura K, Inoue H, Takeuchi M, Medical hypotheses, 64:1202-1204, Jun. 2005
Elevations of AGE and vascular endothelial growth factor with decreased total antioxidant status in the vitreous fluid of diabetic patients with retinopathy, (Yokoi M), Yamagishi S, Takeuchi M, Ohgami K, Okamoto T, Saito W, Muramatsu M, Imaizumi T, Ohno S, The British journal of ophthalmology., 89: 673-675, Jun. 2005
Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders, (Yamagishi S), Nakamura K, Takeuchi M, Medical hypotheses, 65: 392-394, Apr. 2005
Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer’s disease, (Yamagishi S), Nakamura K, Inoue H, Kikuchi S, Takeuchi M, Medical hypotheses, 64: 1205-1207, Mar. 2005
Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients, (Yamagishi S), Nakamura K, Inoue H, Kikuchi S, Takeuchi M, Medical hypotheses, 64: 1208-1210, Mar. 2005
Nifedipine inhibits tumor necrosis factor-alpha-induced upregulation of monocyte chemoattractant protein-1 mRNA levels by suppressing CD40 expression in endothelial cells, (Yamagishi S), Takeuchi M, Drugs under experimental and clinical research, 31: 13-17, Feb. 2005
Atheroprotective properties of nifedipine., (Yamagishi S), Takeuchi M, International journal of tissue reactions, 27:63-67, Feb. 2005
Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property, (Yamagishi S), Takeuchi M, Medical hypotheses, 64: 476-478, Jan. 2005
Pigment epithelium-derived factor (PEDF) inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes, (Amano S), Yamagishi S, Inagaki Y, Nakamura K, Takeuchi M, Inoue H, Imaizumi T, Microvascular research, 69: 45-55, Jan. 2005
Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrom, (Yamagishi S), Nakamura K, Takeuchi M, Medical hypotheses, 65: 152-154, Jan. 2005
Receptor for advanced glycation end products is a promising target of diabetic nephropathy, (Yamamoto Y), Doi T, Kato I, Shinohara H, Sakurai S, Yonekura H, Watanabe T, Myint KM, Harashima A, Takeuchi M, Takasawa S, Okamoto H, Hashimoto N, Asano M, Yamamoto H, Annals of the New York Academy of Sciences., 1043: 562-566, 2005
Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling, (Yamagishi S), Abe R, Inagaki Y, Nakamura K, Sugawara H, Inokuma D, Nakamura H, Shimizu T, Takeuchi M, Yoshimura A, Bucala R, Shimizu H, Imaizumi T, The American journal of pathology., 165: 1865-1874, Dec. 2004
AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction, (Fukami K), Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, Motomiya Y, Bucala R, Iida S, Tamaki K, Imaizumi T, Cooper ME, Okuda S, Kidney international., 66: 2137-2147, Dec. 2004
Glyceraldehyde-derived advanced glycation end products in Alzheimer’s disease, (Choei H), Sasaki N, Takeuchi M, Yoshida T, Ukai W, Yamagishi S, kikuchi S, Saito T, Acta neuropathologica., 108: 189-193, Sep. 2004
Reduced cell replication and induction of apoptosis by advanced glycation end products in rat Schwann cells, (Sekido H), Suzuki T, Jomori T, Takeuchi M, Yabe-Nishimura C, Yagihashi S, Biochemical and biophysical research communications, 320: 241-248, Jul. 2004
Advanced glycation end products increase collagen-specific chaperone protein in mouse diabetic nephropathy, (Ohashi S), Abe H, Takahashi T, Yamamoto Y, Takeuchi M, Arai H, Nagata K, Kita T, Okamoto H, Yamamoto H, Doi T, The Journal of biological chemistry., 279: 19816-19823, May 2004
Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in viv, (Abe R), Shimizu T, Yamagishi S, Shibaki A, Amano S, Inagaki Y, Watanabe H, Sugawara H, Nakamura H, Takeuchi M, Imaizumi T, Shimizu H, The American journal of pathology., 164: 1225-1232, Apr. 2004
Nifedipine inhibits tumor necrosis factor-alpha-induced leukocyte adhesion to endothelial cells by suppressing vascular cell adhesion molecule-1 (VCAM-1) expression, (Yamagishi S), Takeuchi M, Drugs under experimental and clinical research, 30: 163-168, Apr. 2004
Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation, (Yamagishi S), Takeuchi M, Drugs under experimental and clinical research, 30: 169-175, Apr. 2004
TAGE (toxic AGEs) hypothesis in various chronic diseases, Takeuchi M, Yamagishi S, Medical hypotheses, 63: 449-452, Mar. 2004
Alternative routes for the formation of glyceraldehyde-derived AGEs (TAGE) in vivo, Takeuchi M, Yamagishi S, Medical hypotheses, 63: 453-455, Mar. 2004
Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions, (Abe R), Shimizu T, Sugawara H, Watanabe H, Nakamura H, Choei H, Sasaki N, Yamagishi S, Takeuchi M, Shimizu H, The Journal of investigative dermatology, 122: 461-467, Feb. 2004
Molecular mechanism for accelerated atherosclerosis in diabetes and its potential therapeutic intervention, (Yamagishi S), Nakamura K, Takeuchi M, Imaizumi T, International journal of clinical pharmacology research, 24: 129-134, Feb. 2004
Involvement of advanced glycation end-products (AGEs) in Alzheimer’s disease, Takeuchi M, Kikuchi S, Sasaki N, Suzuki T, Watai T, Iwaki M, Bucala R, Yamagishi S, Current Alzheimer research, 1: 39-46, Feb. 2004
Advanced glycation end product (AGE) inhibitors and their therapeutic implications in disease, Takeuchi M, Yamagishi S, Iwaki M, Inagaki Y, Nakamura K, Imaizumi T, International journal of clinical pharmacology research, 24: 95-101, Feb. 2004
Is pigment epithelium-derived factor level in cerebrospinal fluid a promising biomarker for early diagnosis of Alzheimer’s disease?, (Yamagishi S), Inagaki Y, Takeuchi M, Sasaki N, Medical hypotheses, 63:115-117, Jan. 2004
Inhibition of protein kinase C might be harmful to diabetic retinopathy., (Yamagishi S), Takeuchi M, Medical hypotheses, 63:135-137, Jan. 2004
AGE down-regulation of monocyte RAGE expression and its association with diabetic complications in type 1 diabetes, (Miura J), Ychigata Y, Yamamoto Y, Takeuchi M, Sakurai S, Watanabe T, Yonekura H, Yamagishi S, Makita Z, Sato A, Omori Y, Yamamoto H, Iwamoto Y, Journal of diabetes and its complications., 18: 53-59, Jan. 2004
Neurotoxicity of acetaldehyde-derived advanced glycation end products for cultured cortical neurons, Takeuchi M, Watai T, Sasaki N, Choei H, Iwaki M, Ashizawa T, Inagaki Y, Yamagishi S, kikuchi S, Riederer P, Saitop T, Bucala R, Kameda Y, Journal of neuropathology and experimental neurology., 62: 486-496, May 2003
Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy, (Yamagishi S), Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T, International journal of clinical pharmacology research, 23: 129-134, Apr. 2003
Nifedipine inhibits apoptotic cell death of cultured endothelial cells induced by tumor necrosis factor-alpha, (Yamagishi S), Inagaki Y, Abe R, Kikuchi S, Sasaki N, Takeuchi M, Drugs under experimental and clinical research, 29: 141-145, Apr. 2003
Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties, (Yamagishi S), Amano S, Inagaki Y, Okamoto T, Takeuchi M, Inoue H, Microvascular research, 65: 186-190, Mar. 2003
Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury, (Yonekura H), Yamamoto Y, Sakurai S, Petrova RG, Abedin MJ, Li H, Yasui K, Takeuchi M, Makita Z, Takasawa S, Okamoto H, Watanabe T, Yamamoto H, The Biochemical journal., 370: 1097-1109, Mar. 2003
Glycation--a sweet tempter for neuronal death, (Kikuchi S), Shinpo K, Takeuchi M, Yamagishi S, Makita Z, Sasaki N, Tashiro K, Brain research reviews, 41: 306-323, Mar. 2003
Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation, (Inagaki Y), Yamagishi S, Okamoto T, Takeuchi M, Amano S, Diabetologia, 46: 284-287, Feb. 2003
Effect of proteasome inhibitor on cultured mesencephalic dopaminergic neurons, (Kikuchi S), Shinpo K, Tsuji S, Takeuchi M, Yamagishi S, Makita Z, Niino M, Yabe I, Tashiro K, Brain research., 964: 228-236, Feb. 2003
Angiotensin II-type 1 receptor interaction upregulates vascular endothelial growth factor messenger RNA levels in retinal pericytes through intracellular reactive oxygen species generation, (Yamagishi S), Amano S, Inagaki Y, Okamoto T, Inoue H, Takeuchi M, Choei H, Sasaki N, Kikuchi S, Drugs under experimental and clinical research, 29: 75-80, Feb. 2003
Advanced glycation end products inhibit de novo protein synthesis and induce TGF-beta overexpression in proximal tubular cells, (Yamagishi S), Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Kidney international., 63: 464-473, Feb. 2003
Serum leveles of non-carboxymethyllysine advanced glycation endproducts are correlated to severity of microvascular complications in patients with Type 1 diabetes, (Miura J), Yamagishi S, Uchigata Y, Takeuchi M, Yamamoto H, Makita Z, Iwamoto Y, Journal of diabetes and its complications., 17: 16-21, Jan. 2003
Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin, (Okamoto T), Yamagishi S, Inagaki Y, Amano S, Koga K, Abe R, Takeuchi M, Ohno S, Yoshimura A, Makita Z, The FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 16: 1928-1930, Dec. 2002
Sorbitol dehydrogenase overexpression potentiates glucose toxicity to cultured retinal pericytes, (Amano S), Yamagishi S, Kato N, Inagaki Y, Okamoto T, Makino M, Taniko K, Hirooka H, Jomori T, Takeuchi M, Biochemical and biophysical research communications, 299: 183-188, Nov. 2002
CS-866, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats, (Koga K), Yamagishi S, Takeuchi M, Inagaki Y, Amano S, Okamoto T, Saga T, Makita Z, Yoshizuka M, Molecular medicine (Cambridge, Mass.), 8: 591-599, Nov. 2002
Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes, (Petrova R), Yamamoto Y, Muraki K, Yonekura H, Sakurai S, Watanabe T, Li H, Takeuchi M, Makita Z, Kato I, Takasawa S, Okamoto H, Imaizumi Y, Yamamoto H, Journal of molecular and cellular cardiology., 34: 1425-1431, Oct. 2002
Incadronate disodium inhibits advanced glycation end products-induced angiogenesis in vitro, (Okamoto T), Yamagishi S, Inagaki Y, Amano S, Takeuchi M, Kikuchi S, Ohna S, Yoshimura A, Biochemical and biophysical research communications, 297: 419-424, Sep. 2002
Beraprost sodium, a prostaglandin I2 analogue, protects against advanced glycation end products-induced injury in cultured retinal pericytes, (Yamagishi S), Amano S, Inagaki Y, Okamoto T, Takeuchi M, Makita Z, Molecular medicine (Cambridge, Mass.), 8: 546-550, Sep. 2002
Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties, (Yamagishi S), Inagaki Y, Amano S, Okamoto T, Takeuchi M, Makita Z, Biochemical and biophysical research communications, 296: 877-882, Aug. 2002
Aminoguanidine pyridoxal adduct is superior to aminoguanidine for preventing diabetic nephropathy in mice., (Miyoshi H), Taguchi T, Sugiura M, Takeuchi M, Yanagisawa K, Watanabe Y, Miwa I, Makita Z, Koike T, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 34: 371-377, Jul. 2002
Dilazep hydrochloride, an antiplatelet drug, prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats, (Yamagishi S), Koga K, Inagaki Y, Amano S, Okamoto T, Takeuchi M, Drugs under experimental and clinical research, 28: 221-227, Jun. 2002
Detection of N epsilon-(carboxymethyl)lysine (CML) and non-CML advanced glycation end-products in the anterior horn of amyotrophic lateral sclerosis spinal cord, (Kikuchi S), Shinpo K, Ogata A, Tsuji S, Takeuchi M, Makita Z, Tashiro K, Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases, 3: 63-68, Jun. 2002
Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques, (Sasaki N), Takeuchi M, Choei H, Kikuchi S, Hayashi Y, Nakano N, Ikeda H, Yamagishi S, Kitamoto T, Saito T, Makita Z, Neuroscience letters., 326: 117-120, Jun. 2002
Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human cultured mesangial cells, (Yamagishi S), Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, Makita Z, The Journal of biological chemistry., 277: 20309-20315, Jun. 2002
Up-regulation of vascular endothelial growth factor and down-regulation of pigment epithelium-derived factor messenger ribonucleic acid levels in leptin-exposed cultured retinal pericytes, (Yamagishi S), Inagaki Y, Amano S, Okamoto T, Takeuchi M, International journal of tissue reactions, 24: 137-142, Apr. 2002
Palmitate-induced apoptosis of microvascular endothelial cells and pericytes, (Yamagishi S), Okamoto T, Amano S, Inagaki Y, Koga K, Choei H, Sasaki N, Kikuchi S, Takeuchi M, Makita Z, Molecular medicine (Cambridge, Mass.), 8: 179-184, Apr. 2002
Effect of geranylgeranylaceton on cellular damage induced by proteasome inhibition in cultured spinal neurons, (Kikuchi S), Shinpo K, Takeuchi M, Tsuji S, Yabe I, Niino M, Tashiro K, Journal of neuroscience research., 69: 373-381, Mar. 2002
Serum levels of glucose-derived advanced glycation end products are associated with the severity of diabetic retinopathy in type 2 diabetic patients without renal dysfunction, (Koga K), Yamagishi S, Okamoto T, Inagaki Y, Amano S, Takeuchi M, Makita Z, International journal of clinical pharmacology research, 22: 13-17, Jan. 2002
Advanced glycation end products-induced apoptosis and overexpression of vascular endothelial growth factor in bovine retinal pericytes, (Yamagishi S), Amano S, Inagaki Y, Okamoto T, Koga K, Sasaki N, Yamamoto H, Takeuchi M, Makita Z, Biochemical and biophysical research communications, 290: 973-978, Jan. 2002
Immunological detection of a novel advanced glycation end-product, Takeuchi M, Yanase Y, Matsuura N, Yamagishi S, Kameda Y, Bucala R, Makita Z, Molecular medicine (Cambridge, Mass.), 7: 783-791, Nov. 2001
Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice, (Yamamoto Y), Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M, Watanabe T, Yamagishi S, Sakurai S, Takasawa S, Okamoto H, Yamamoto H, The Journal of clinical investigation, 108: 261-268, Jul. 2001
Effect of OPB-9195, anti-glycation agent, on experimental diabetic neuropathy, (Wada R), Nishizawa Y, Yagihashi N, Takeuchi M, Ishikawa Y, Yasumura K, Nakano M, Yagihashi S, European journal of clinical investigation, 31: 513-520, Jun. 2001
Alternative routes for the formation of immunochemically distinct advanced glycation end-products in vivo, Takeuchi M, Makita Z, Current molecular medicine, 1: 305-315, Jun. 2001
Increased levels of vascular endothelial growth factor and advanced glycation end products in aqueous humor of patients with diabetic retinopathy, (Endo M), Yanagisawa K, Tsuchida K, Okamoto T, Matsushita T, higuchi M, Matsuda A, Takeuchi M, Makita Z, Koike T, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme., 33: 317-322, May 2001
Can we identify genes for susceptibility to diabetic microangiopathies using stroke-prone spontaneously hypertensive rat models?, (Yamagishi S), Takeuchi M, Unoki H, Medical hypotheses, 56:510-512, Apr. 2001
Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer’s disease, (Sasaki N), Toki S, Choei H, Saito T, Nakano N, Hayashi Y, Takeuchi M, Makita Z, Brain research., 888: 256-262, Jan. 2001
Advanced glycation end products and the pathogenesis of diabetic nephropathy., (Yamagishi S), Takeuchi M, Makita Z, Contributions to nephrology, 134:30-35, 2001
Neurotoxicity of advanced glycation end-products for cultured cortical neurons, Takeuchi M, Bucala R, Suzuki T, Ohkubo T, Yamagzaki M, Koike T, Kameda Y, Makita Z, Journal of neuropathology and experimental neurology., 59: 1094-1105, Dec. 2000
Immunological evidence that non-carboxymethyllysine advanced glycation end-products are produced from short chain sugars and dicarbonyl compounds in vivo, Takeuchi M, Makita Z, Bucala R, Suzuki T, Koike T, Kameda Y, Molecular medicine (Cambridge, Mass.), 6: 114-125, Feb. 2000
Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients, Takeuchi M, Makita Z, Yanagisawa K, Kameda Y, Koike T, Molecular medicine (Cambridge, Mass.), 5: 393-405, Jun. 1999
Specific fluorescence assay for advanced glycation end products in blood and urine of diabetic patients., (K.Yanagisawa), Z.Makita, K.Shiroshita, T.Fusegawa, S.Kuwajima, M.Takeuchi, T.Koike, Metabolism: clinical and experimental, 47:1348-1353, Nov. 1998
Preparation and biological activity of manno- and galacto-validamines, new 5a-carba-glycosylamines as α-glycosidase inhibitors., (Kameda Y), Kawashima K, Takeuchi M, Ikeda K, Asano N, Matsui K, Carbohydrate research, 300:259-264, 1997
Interactions of Escherichia coli endonuclease IV and exonuclease III with abasic sites in DNA., Takeuchi M, Lillis R, Demple B, Takeshita M, The Journal of biological chemistry., 269:21907-21914, 1994
Trehalase inhibitors, validoxylamine A and related compounds as insecticides., (Asano N), Takeuchi M, Kameda Y, Matsui K, Kono Y, The Journal of antibiotics, 43:722-726, 1990
Purification and some properties of cytochrome c550 from Flavobacterium saccharophilum., Takeuchi M, Matsui K, Biological & pharmaceutical bulletin, 38:1098-1099, 1990
Inhibitory effect of validamine, valienamine, and valiolamine on activities of carbohydrases in rat small intestinal brush border membranes., Takeuchi M, Takai N, Asano N, Kameda K, Matsui K, Biological & pharmaceutical bulletin, 38:1970-1972, 1990
Inhibitory effect of pseudo-aminosugars on oligosaccharide glucosidases I and II and on lysosomal α-glucosidase from rat liver., Takeuchi M, Kamata K, Yoshida M, Kameda Y, Matsui K, Journal of biochemistry., 108:42-46, 1990
Chemical modification by 2,4,6-trinitrobenzene-sulfonic acid (TNBS) of an essential amino groups in 3-ketovalidoxylamine A C-N lyase., Takeuchi M, Neyazaki K, Matsui K, Biological & pharmaceutical bulletin, 38:1419-1420, 1990
Preparation of 3-amino-3-deoxy derivatives of trehalose and sucrose and their activities., (Asano N), Katayama K, Takeuchi M, Furumoto T, Kameda K, Matsui K, The Journal of antibiotics, 42:585-590, 1989
Purification and properties of soluble D-glucoside 3-dehydrogenase from Flavobacterium saccharophilum., Takeuchi M, Asano N, Kameda Y, Matsui K, Bioscience, biotechnology, and biochemistry, 52:1905-1912, 1988
Physiological role of glucoside 3-dehydrogenase and cytochrome c551 in the sugar oxidizing system of Flavobacterium saccharophilum., Takeuchi M, Asano N, Kameda Y, Matsui K, Journal of biochemistry., 103:938-943, 1988
Fluorometric studies on the role of calcium in substrate binding to 3-ketovalidoxylamine A C-N lyase., Takeuchi M, Asano N, Kameda Y, Matsui K, Biological & pharmaceutical bulletin, 36:3540-3545, 1988
Purification and properties of glucoside 3-dehydrogenase from Flavobacterium Saccharophilum., Takeuchi M, Ninomiya K, Kawabata K, Asano N, Kameda Y, Matsui K, Journal of biochemistry., 100:1049-1055, 1986
Chemical modification by diethylpyrocarbonate of an essential histidine residues in 3-ketovalidoxylamine A C-N lyase., Takeuchi M, Asano N, Kameda Y, Matsui K, Journal of biochemistry., 99:1571-1577, 1986
Purification and properties of 3-ketovalidoxylamine A C-N lyase from Flavobacterium saccharophilum., Takeuchi M, Asano N, Kameda Y, Matsui K, Journal of biochemistry., 98:1631-1638, 1985
Epivaliolamine and deoxyvalidamine, new pseudo-aminosugars produced by Streptomyces hygroscopicus., (Kameda Y), Asano N, Takeuchi M, Yamaguchi T, Matsui K, Horii S, Fukase H, The Journal of antibiotics, 38:1816-1818, 1985
Valiolamine, a new α-glucosidase inhibiting aminocyclitol produced by Streptomyces hygroscopicus., (Kameda Y), asano N, Yoshikawa M, Takeuchi M, Yamaguchi T, Matsui K, Horii S, Fukase H, The Journal of antibiotics, 37:1301-1307, 1984
Studies on cation-induced membrane vesicle aggregation of porcine intestinal brush borders., (Ohyashiki T), Takeuchi M, Mohri T, Journal of biochemistry., 95:881-886, 1984
Microbial degradation of validamicin A by Flavobacterium saccharophilum－Enzymatic cleavage of C-N linkage in validoxylamine A－., (Asano N), Takeuchi M, Ninomiya K, Kameda Y, Matsui K, The Journal of antibiotics, 37:859-867, 1984
A conformation change of the porcine intestinal calcium binding protein on binding of Ca2+., (Chiba K), Takeuchi M, Mohri T, Ohayshiki T, Biological & pharmaceutical bulletin, 31:966-970, 1983
Temperature-induced transitions of porcine intestinal brush border membranes., (Ohyashiki T), Takeuchi M, Kodera M, Mohri T, Biochimica et biophysica acta-molecular and cell biology of lipids, 688:16-22, 1982
Protective Effects of Collagen Tripeptides in Human Aortic Endothelial Cells by Restoring ROS-Induced Transcriptional Repression, Hidehito Saito-Takatsuji, Yasuo Yoshitomi, Yasuhito Ishigaki, Shoko Yamamoto, Noriaki Numata, Yasuo Sakai, Masayoshi Takeuchi, Naohisa Tomosugi, Shogo Katuda, hideto Yonekura, Takayuki Ikeda, Nutrients, 13:2226, Jun. 2021
Accumulation of toxic advanced glycation end-products induces cytotoxicity and inflammation in hepatocyte-like cells differentiated from human induced pluripotent stem cells., (Kikuchi C), Sakasai-Sakai A, Okimura R, Tanaka H, Takata T, Takeuchi M, Matsunaga T, Biol. Pharm. Bull., 44:1399-1402, Oct. 2021
Serum levels of 1,5-anhydroglucitol and 1,5-anhydrofructose-derived advanced glycation end products in patients undergoing hemodialysis., (Tanaka K), Sakasai-Sakai A, Motomiya Y, Yoneda T, Takeuchi M, 13:85, Aug. 2021
Intracellular toxic AGEs (TAGE) triggers numerous types of cell damage., Takeuchi M, Sakasai-Sakai A, Takata T, Takino J, Koriyama Y, Furukawa A, Kikuchi C, Nagamine K, Hori T, Matsunaga T, Biomolecules, 11:387, Mar. 2021
Suppression of hepatic stellate cell death by toxic advanced glycation end-products., (Takino J), Sato T, Nagamine K, Sakasai-Sakai A, Takeuchi M, Hori T, Biol. Pharm. Bull., 44:112-117, Jan. 2021
RasGRP2 inhibits glyceraldehyde-derived toxic advanced glycation end-products from inducing permeability in vascular endothelial cells., (Takino J), Sato T, Kanetaka T, Okihara K, Nagamine K, Takeuchi M, Hori T, Sci. Rep., 11:2959, Feb. 2021
Trapa bispinosa Roxb. extract lowers advanced glycation end-products and increases live births in older patients with assisted reproductive technology: a randomized controlled trial., (Jinno M), Nagai R, Takeuchi M, Watanabe A, Teruya K, Sugawa H, Hatakeyama N, Jinno Y, Reprod. Biol. Endocrinol., 19:149, Sep. 2021
Intracellular Toxic Advanced Glycation End-Products in 1.4E7 Cell Line Induce Death with Reduction of Mirotubule-Associated Protein 1 Light Chain 3 and p62, Takanobu Takata, Akiko Sakasai-Sakai, Masayoshi Takeuchi, 14:332, Jan. 2022
Intracellular Toxic Advanced Glycation End-Products May Induce Cell Death and Suppress Cardiac Fibroblasts, Takanobu Takata, Akiko Sakasai-Sakai, Masayoshi Takeuchi, 12:615, Jul. 2022
Effects of Toxic AGEs (TAGE) on Human Health, Masayoshi Takeuchi, Akiko Sakasai-Sakai, Takanobu Takata, 11:2178, Jul. 2022
Pyridoxamine and aminoguanidine attenuate the abnormal aggregation of β-tubulin and suppression of neurite outgrowth by glyceraldehyde-derived toxic advanced glycation end-products., 13:　, Jun. 2022
The association between accumulation of toxic advanced glycation end-products and cytotoxic effect in MC3T3-E1 cells., 14:990, Feb. 2022
Effects of toxic AGEs (TAGE) on human health., 11:2178, Jul. 2022
Pre-diagnostic serum glyceraldehyde-derived advanced glycation end products and mortality among colorectal cancer patients., Mao Z, Baker JR, Takeuchi M, Hyogo H, Tjønneland A, Eriksen AK, Severi G, Rothwell J, Laouali N, Katzke V, Kaaks R, Schulze MB, Palli D, Sieri S, de Magistris MS, Tumino R, Sacerdote C, Derksen JWG, Gram IT, Skeie G, Sandanger TM, Quirós JR, Crous-Bou M, Sánchez MJ, Amiano P, Colorado-Yohar SM, Guevara M, Harlid S, Johansson I, Perez-Cornago A, Freisling H, Gunter M, Weiderpass E, Heath AK, Aglago E, Jenab M, Fedirko V, International Journal of Cancer, 152:2257-2268, Jun. 2023
Involvement of intercellular TAGE and the TAGE-RAGE-ROS axis in the onset and progression of NAFLD/NASH., Sakasai-Sakai A, Takeda K, Takeuchi M, Antioxidants, 12:748, Mar. 2023
A Novel Approach: Investigating the Intracellular Clearance Mechanism of Glyceraldehyde-Derived Advanced Glycation End-Products Using the Artificial Checkpoint Kinase 1 d270KD Mutant as a Substrate Model, Kenji Takeda, Akiko Sakai-Sakasai, Kouji Kajinami, Masayoshi Takeuchi, Cells, 12:2838-2838, Dec. 2023
Structures of Toxic Advanced Glycation End-Products Derived from Glyceraldehyde, A Sugar Metabolite, Akiko Sakai-Sakasai, Kenji Takeda, Hirokazu Suzuki, Masayoshi Takeuchi, 14:202-202, Feb. 2024
Toxic advanced glycation end-products inhibit axonal elongation mediated by β-tubulin aggregation in mice optic nerves., (Ooi H), Furukawa A, Takeuchi M, Koriyama Y., 25:7409, Jul. 2024
Major generation route of cytotoxic protein adducts derived from acetaldehyde, a metabolite of alcohol., Takeuchi M, Suzuki H, Sakai-Sakasai A, 189:111385, Aug. 2024
Toxic advanced glycation end-products (TAGE) are major structures of cytotoxic AGEs derived from glyceraldehyde., Takeuchi M, Suzuki H, Takeda K, Sakai-Sakasai, 183:111248, Feb. 2024
Effect of anagliptin on vascular injury in the femoral artery of type 2 diabetic rats., (Noda M), Kikuchi C, Hori E, Iwao T, Nagami C, Takeuchi M, Matsunaga T, 47:204-212, Jan. 2024
Toxic AGEs (TAGE) cause lifestyle-related diseases., Takeuchi M., 13:1372, Nov. 2024
Structures of toxic advanced glycation end-products derived from glyceraldehyde, a sugar metabolite., Sakai-Sakasai A, Takeda K, Suzuki H, Takeuchi M., 14:202, Feb. 2024
Glycation stress induced by glyceraldehyde promotes vimentin accumulation and disrupts aggresome clearance in Hep3B cells, Akiko Sakai-Sakasai, Kenji Takeda, Masayoshi Takeuchi, Biochemical and Biophysical Research Communications, 829:154173-154173, Sep. 2026

Books etc

Role of advanced glycation end products (AGEs) in cell growth and death
Focus on Cell Apoptosis Research, Daniel W. Cho eds.,
(Yamagishi S), Nakamura K, Matsui T, Inoue H, Makino T, Shimizu T, Takeuchi M
Nova Science 2006
Pericytes and angiogenesis
Progress in angiogenesis research
(Yamagishi S), Inagaki Y, Nakamura K, Takeuchi M, Imaizumi T
Nova Science 2004

Note: Performance information for the past 1-2 years may be revised at a later date due to inspections conducted by the committee from July to September every year.